Shanghai Zhangjiang Science & Technology Venture Capital

The firm's physical location inside the park — Shanghai's largest concentration of semiconductor fabs, biotech labs, and software R&D centers — shapes its entire origination model. Rather than sourcing deals from a central office, it identifies startups through park-property relationships, shared-infrastructure usage, and tenant growth trajectories. This proximity means the firm can observe a company's laboratory expansion or cleanroom buildout before a formal fundraising process begins, creating a diligence timeline unavailable to off-park investors.

It operates as a venture capital arm of the Zhangjiang Group, which is the state-owned master developer of Zhangjiang Hi-Tech Park under the Shanghai municipal government. While its capital ultimately traces to public-sector sources, the firm functions with investment-committee governance and makes equity investments on commercial terms, similar to other Chinese state-affiliated venture platforms. It does not operate as a grant-making body or pure policy bank.

The firm covers the full early-stage spectrum — seed, start-up, and expansion rounds — occasionally extending into later growth financing for companies that originated in the park. Seed-stage commitments often back academic research teams commercializing IP from nearby universities, while expansion capital supports companies adding manufacturing lines or expanding into other Chinese technology corridors. It does not typically participate in pre-IPO crossover rounds.

Semiconductors, biotechnology, and enterprise software constitute the historical core, reflecting Zhangjiang Park's anchor tenants and the Shanghai municipal government's industrial priorities. Advanced manufacturing, particularly precision equipment used in chip fabrication, is also a recurring theme. The firm has been less active in consumer internet and pure marketplace models, which are better served by the venture ecosystem in Beijing and Shenzhen.

The firm predominantly makes direct equity investments rather than committing as a limited partner into independent venture funds. When external co-investors are involved, they tend to be other state-affiliated platforms, corporate venture arms of semiconductor or pharmaceutical companies, or select domestic RMB funds with complementary stage mandates. Foreign VC co-investment is uncommon given the structure of the underlying portfolio companies.